The safety of daclatasvir for the treatment of hepatitis C

Document Type

Article

Publication Date

1-1-2015

Publication Title

Expert opinion on drug safety

Abstract

INTRODUCTION: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against hepatitis C.

AREAS COVERED: We review current literature including published abstracts and manuscripts. Evidence was obtained through PubMed/Medline search using listed keywords and through review of published abstracts.

EXPERT OPINION: Daclatasvir introduces a degree of pangenotypic potency currently lacking in other NS5A agents. Emerging literature suggests that daclatasvir in combination with other DAAs will represent a promising option in this difficult to treat populations including posttransplant, genotype 3 and HIV patients.

Medical Subject Headings

Administration, Oral; Animals; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Virus Replication

PubMed ID

26571362

Volume

14

Issue

11

First Page

1787

Last Page

1797

Find It @ Sladen

Share

COinS